Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 497

1.

What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?

Flowers CR, Ramsey SD.

J Clin Oncol. 2018 Oct 2:JCO2018793570. doi: 10.1200/JCO.2018.79.3570. [Epub ahead of print] No abstract available.

PMID:
30277825
2.

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.

Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ.

Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1515944. [Epub ahead of print]

PMID:
30277110
3.

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, Evens AM, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD.

Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1515940. [Epub ahead of print]

PMID:
30277102
4.

The Association of Physical Activity Before and After Lymphoma Diagnosis with Survival Outcomes.

Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, Thompson CA.

Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25288. [Epub ahead of print]

PMID:
30230581
5.

Decreased Food and Water Intake Attributable to Failing Sanitation in the United States.

Flowers CC.

Am J Public Health. 2018 Oct;108(10):1269. doi: 10.2105/AJPH.2018.304688. No abstract available.

PMID:
30207775
6.

Reply to J.A. Talcott.

Taplitz RA, Kennedy EB, Flowers CR.

J Clin Oncol. 2018 Sep 4:JCO2018793141. doi: 10.1200/JCO.2018.79.3141. [Epub ahead of print] No abstract available.

PMID:
30179568
7.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR.

J Clin Oncol. 2018 Sep 4:JCO1800374. doi: 10.1200/JCO.18.00374. [Epub ahead of print]

PMID:
30179565
8.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Summary.

Taplitz RA, Kennedy EB, Flowers CR.

J Oncol Pract. 2018 Sep 4:JOP1800366. doi: 10.1200/JOP.18.00366. [Epub ahead of print] No abstract available.

PMID:
30179525
9.

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.

Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B.

Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6.

PMID:
30122201
10.

Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States.

Blum KA, Keller FG, Castellino S, Phan A, Flowers CR.

Br J Haematol. 2018 Aug 10. doi: 10.1111/bjh.15532. [Epub ahead of print]

PMID:
30095154
11.

Clusterin from human clinical tear samples: Positive correlation between tear concentration and Schirmer strip test results.

Yu V, Bhattacharya D, Webster A, Bauskar A, Flowers C, Heur M, Chintala SK, Itakura T, Wilson MR, Barr JT, Jeong S, Wang M, Fini ME.

Ocul Surf. 2018 Oct;16(4):478-486. doi: 10.1016/j.jtos.2018.08.001. Epub 2018 Aug 2.

12.

History of autoimmune conditions and lymphoma prognosis.

Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR.

Blood Cancer J. 2018 Aug 1;8(8):73. doi: 10.1038/s41408-018-0105-4.

13.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR.

Ann Oncol. 2018 Sep 1;29(9):1932-1938. doi: 10.1093/annonc/mdy256.

14.

Disparities in survival by insurance status in follicular lymphoma.

Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR.

Blood. 2018 Sep 13;132(11):1159-1166. doi: 10.1182/blood-2018-03-839035. Epub 2018 Jul 24.

PMID:
30042094
15.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR.

J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.

PMID:
29975624
16.

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.

Hall KH, Panjic EH, Valla K, Flowers CR, Cohen JB.

Oncology (Williston Park). 2018 Jun;32(6):303-9. Review.

17.

Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.

Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, Epperla N, Fenske TS, Hamadani M, Flowers CR, Cohen JB.

Leuk Lymphoma. 2018 Jun 18:1-9. doi: 10.1080/10428194.2018.1455973. [Epub ahead of print]

PMID:
29912594
18.

The need to assess financial adverse events.

Nastoupil LJ, Prasad V, Flowers CR.

Lancet Haematol. 2018 Jun 12. pii: S2352-3026(18)30072-3. doi: 10.1016/S2352-3026(18)30072-3. [Epub ahead of print] No abstract available.

PMID:
29907551
19.

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B.

Ann Oncol. 2018 Aug 1;29(8):1822-1827. doi: 10.1093/annonc/mdy203.

PMID:
29897404
20.

Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Valla K, Flowers CR, Koff JL.

Expert Opin Investig Drugs. 2018 Jun;27(6):513-522. doi: 10.1080/13543784.2018.1482273. Epub 2018 Jun 7. Review.

PMID:
29855199
21.

Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.

Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA.

CA Cancer J Clin. 2018 Jul;68(4):250-281. doi: 10.3322/caac.21457. Epub 2018 May 30.

22.

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.

Wang SS, Carrington M, Berndt SI, Slager SL, Bracci PM, Voutsinas J, Cerhan JR, Smedby KE, Hjalgrim H, Vijai J, Morton LM, Vermeulen R, Paltiel O, Vajdic CM, Linet MS, Nieters A, de Sanjose S, Cozen W, Brown EE, Turner J, Spinelli JJ, Zheng T, Birmann BM, Flowers CR, Becker N, Holly EA, Kane E, Weisenburger D, Maynadie M, Cocco P, Albanes D, Weinstein SJ, Teras LR, Diver WR, Lax SJ, Travis RC, Kaaks R, Riboli E, Benavente Y, Brennan P, McKay J, Delfau-Larue MH, Link BK, Magnani C, Ennas MG, Latte G, Feldman AL, Doo NW, Giles GG, Southey MC, Milne RL, Offit K, Musinsky J, Arslan AA, Purdue MP, Adami HO, Melbye M, Glimelius B, Conde L, Camp NJ, Glenn M, Curtin K, Clavel J, Monnereau A, Cox DG, Ghesquières H, Salles G, Bofetta P, Foretova L, Staines A, Davis S, Severson RK, Lan Q, Brooks-Wilson A, Smith MT, Roman E, Kricker A, Zhang Y, Kraft P, Chanock SJ, Rothman N, Hartge P, Skibola CF.

Cancer Res. 2018 Jul 15;78(14):4086-4096. doi: 10.1158/0008-5472.CAN-17-2900. Epub 2018 May 7.

23.

Ethnic disparity in primary cutaneous CD30+ T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database.

Feldman AL, Flowers CR.

Br J Haematol. 2018 Jun;181(6):721-722. doi: 10.1111/bjh.15221. Epub 2018 Apr 20. No abstract available.

PMID:
29676455
24.

Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors.

Keegan THM, Li Q, Steele A, Alvarez EM, Brunson A, Flowers CR, Glaser SL, Wun T.

Cancer Causes Control. 2018 Jun;29(6):551-561. doi: 10.1007/s10552-018-1025-0. Epub 2018 Apr 13.

PMID:
29654427
25.

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.

Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW.

Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15149. [Epub ahead of print] No abstract available.

PMID:
29611177
26.

Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.

Becnel M, Flowers CR, Nastoupil LJ.

Ann Lymphoma. 2017 Nov;1. pii: 8. doi: 10.21037/aol.2017.11.01. Epub 2017 Nov 17.

27.

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM.

Neurology. 2018 May 1;90(18):e1548-e1552. doi: 10.1212/WNL.0000000000005422. Epub 2018 Mar 30.

PMID:
29602912
28.

Impact of the posttransplant lymphoproliferative disorder subtype on survival.

Koff JL, Li JX, Zhang X, Switchenko JM, Flowers CR, Waller EK.

Cancer. 2018 Jun 1;124(11):2327-2336. doi: 10.1002/cncr.31339. Epub 2018 Mar 26.

PMID:
29579330
29.

Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.

Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ, Blum KA, Grover NS, Mathews SP, Gordon MJ, Danilov AV, Epperla N, Fenske TS, Hamadani M, Park SI, Flowers CR, Cohen JB.

Cancer. 2018 Jun 1;124(11):2306-2315. doi: 10.1002/cncr.31328. Epub 2018 Mar 26.

PMID:
29579328
30.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update Summary.

Taplitz RA, Kennedy EB, Flowers CR.

J Oncol Pract. 2018 Apr;14(4):250-255. doi: 10.1200/JOP.18.00016. Epub 2018 Mar 8. No abstract available.

PMID:
29517953
31.

Balancing patient value and payer cost in hematologic malignancies: can it be done?

Allen PB, Flowers CR.

Expert Rev Pharmacoecon Outcomes Res. 2018 Apr;18(2):123-126. doi: 10.1080/14737167.2018.1444478. Epub 2018 Mar 13. No abstract available.

PMID:
29486601
32.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR.

J Clin Oncol. 2018 May 10;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211. Epub 2018 Feb 20.

PMID:
29461916
33.

3D 7Li magnetic resonance imaging of brain lithium distribution in bipolar disorder.

Smith FE, Thelwall PE, Necus J, Flowers CJ, Blamire AM, Cousins DA.

Mol Psychiatry. 2018 Feb 9. doi: 10.1038/s41380-018-0016-6. [Epub ahead of print]

34.

Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860. [Epub ahead of print]

PMID:
29415595
35.

Comparison of Resting Energy Expenditure Assessment in Pediatric Oncology Patients.

Ringwald-Smith K, Hobar A, Flowers C, Badgett K, Williams-Hooker R, Roach RR, Sykes A, Lu Z, Mackert P, Mandrell BN.

Nutr Clin Pract. 2018 Apr;33(2):224-231. doi: 10.1002/ncp.10002. Epub 2018 Feb 2.

PMID:
29393551
36.

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.

Petersen CT, Hassan M, Morris AB, Jeffery J, Lee K, Jagirdar N, Staton AD, Raikar SS, Spencer HT, Sulchek T, Flowers CR, Waller EK.

Blood Adv. 2018 Feb 13;2(3):210-223. doi: 10.1182/bloodadvances.2017011254.

37.

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.

Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):114-124.e2. doi: 10.1016/j.clml.2017.11.010. Epub 2017 Dec 6.

38.

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR.

Blood Adv. 2017 Nov 28;1(25):2433-2443. doi: 10.1182/bloodadvances.2017011262. eCollection 2017 Nov 28.

39.

Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.

Koff JL, Rai A, Flowers CR.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):e115-e121. doi: 10.1016/j.clml.2017.11.009. Epub 2017 Dec 2.

PMID:
29273217
40.

Effective management strategies for patients with marginal zone lymphoma.

Rosand CB, Valla K, Flowers CR, Koff JL.

Future Oncol. 2018 May;14(12):1213-1222. doi: 10.2217/fon-2017-0480. Epub 2017 Dec 20.

PMID:
29260925
41.

Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.

Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1163-1171. doi: 10.1016/j.bbmt.2017.12.771. Epub 2017 Dec 11.

PMID:
29242111
42.

When to Choose Transplant in Follicular Lymphoma: Navigating a Complex Landscape.

Casulo C, Flowers CR.

J Oncol Pract. 2017 Dec;13(12):808-809. doi: 10.1200/JOP.2017.028340. No abstract available.

PMID:
29232538
43.

Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Chang A, Schlafer D, Flowers CR, Allen PB.

Expert Opin Investig Drugs. 2018 Jan;27(1):55-70. doi: 10.1080/13543784.2018.1416091. Epub 2017 Dec 24. Review.

PMID:
29228840
44.

How are perceptions associated with water consumption in Canadian Inuit? A cross-sectional survey in Rigolet, Labrador.

Wright CJ, Sargeant JM, Edge VL, Ford JD, Farahbakhsh K, Shiwak I, Flowers C, Gordon AC; RICG; IHACC Research Team, Harper SL.

Sci Total Environ. 2018 Mar 15;618:369-378. doi: 10.1016/j.scitotenv.2017.10.255. Epub 2017 Nov 10.

PMID:
29132004
45.

Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.

Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR.

Leuk Lymphoma. 2018 Jul;59(7):1700-1709. doi: 10.1080/10428194.2017.1390230. Epub 2017 Oct 25.

PMID:
29065744
46.

Human Intestinal Parasite Burden and Poor Sanitation in Rural Alabama.

McKenna ML, McAtee S, Bryan PE, Jeun R, Ward T, Kraus J, Bottazzi ME, Hotez PJ, Flowers CC, Mejia R.

Am J Trop Med Hyg. 2017 Nov;97(5):1623-1628. doi: 10.4269/ajtmh.17-0396. Epub 2017 Oct 10.

47.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

48.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
49.

Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.

Lin RJ, Behera M, Diefenbach CS, Flowers CR.

Blood. 2017 Nov 16;130(20):2180-2185. doi: 10.1182/blood-2017-05-736975. Epub 2017 Aug 16. Review. Erratum in: Blood. 2018 Mar 1;131(9):1037.

PMID:
28814386
50.

The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project.

Sargent DJ, Shi Q, Flowers CR, Schmitz N, Habermann TM, Flament J, Fu T, Coiffier B; SEAL group.

Oncologist. 2017 Dec;22(12):1415-1418. doi: 10.1634/theoncologist.2017-0177. Epub 2017 Aug 10. No abstract available.

Supplemental Content

Loading ...
Support Center